Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11857535 Methods of treating mutant lymphomas

Patent 11857535 was granted and assigned to Kymera Therapeutics on January, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Kymera Therapeutics

Current Assignee

Kymera Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

118575350

Patent Inventor Names

Duncan Walker0

Date of Patent

January 2, 2024

Patent Application Number

174440150

Date Filed

July 29, 2021

Patent Citations

‌

US Patent 11065231 Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides

‌

US Patent 7390799 Apoptosis promoters

‌

US Patent 7501496 Anti-OX40L antibodies

‌

US Patent 10874743 IRAK degraders and uses thereof

Patent Primary Examiner

CPC Code

Patent abstract

The present invention relates to methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degrader.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11857535 Methods of treating mutant lymphomas

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API